{'fraction_non_alphanumeric': 0.016697588126159554, 'fraction_numerical': 0.0, 'mean_word_length': 5.585365853658536, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reply to “Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity”

Although further testing in larger series will potentially verify or refute the concerns raised by Cheung et al, we believe that there is a strong biological rationale as well as sufficient data to support the validity of immunerelated adverse events (irAEs) as biomarkers of immunotherapy efficacy as signaled in our retrospective series. A few considerations that we would like to highlight include the following: